6:14 PM
 | 
Dec 05, 2012
 |  BC Extra  |  Company News

NICE now recommends Orencia for second-line RA

The U.K.'s NICE issued draft guidance recommending IV Orencia abatacept from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with methotrexate to treat moderate to severe rheumatoid arthritis (RA) in adults whose disease has responded inadequately to...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >